The content on this site is intended for healthcare professionals only
Dr Richard G. Gray presents data during a press conference at the 2013 ASCO Annual Meeting on the British aTTom study.
The study found ten years of adjuvant treatment with tamoxifen provided women with oestrogen-receptor-positive (ER ) breast cancer greater protection against late recurrence and death than the current standard of only five years of tamoxifen. While side effects are also increased with longer tamoxifen use, the researchers conclude that the overall benefits greatly outweigh the risk of continuing therapy. The findings from aTTom, a Phase III randomized study, complement and confirm the results of the recently published international study, ATLAS.
Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors
Breast cancer survivorship
Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients
Advancements in paediatric Acute lymphoblastic leukemia management
ESMO 2024: Latest in EGFR mutated NSCLC
Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer
Hormonal receptor positive breast cancer adjuvant and metastatic indications
